CLAIMS 1. A method for the treatment of juvenile rheumatoid arthritis; cystic fibrosis, HIV-infection in children receiving HAART treatment (HIVfHALS children); hypochondroplasia; achondroplasia; fractures in or of long bones, such as tibia, fibula, femur, humerus, radius, ulna, clavi-cula, matacarpea, matatareea, and digit; fractures in or of spongious bones, such as the scull, base of hand, and base of food; patients after tendon or ligament surgery in e.g, hand, knee, or shoulder; patients having or going through distraction oteogenesis; patients after hip or discus replacement, meniscus repair, spinal fusions or prosthesis fixation, such as in the knee, hip, shoulder, elbow, wrist or jaw; patients into which osteosynthesis material, such as nails, screws and plates, have been fixed; patients with non-union or mal-union of fractures; patients after osteatomia, e.g, from tibia or 1st toe; patients after graft implantation; articular cartilage degeneration in knee caused by trauma or arthritis; osteoporosis in patients with Turner syndrome; osteoporosis in men; malnutritions! associated cardiovascular disease In APCD; reversal of cachexia in APCD; cancer In APCD; chronic abstractive pulmooal disease in APCD; HIV in APCD; elderly with APCD; chronic liver disease In APCD, fatigue syndrome In APCD; impaired liver function; males with Htv infections; short bowel syndrome; male infertility; patients after major elective surgery, aloohol/dmg detoxification or neurological trauma; osteo-arthritis; or traumatically damaged cartilage, the method composing administering to a patient in need thereof an effective amount of a long-acting growth hormone composition. 2. A method for the acceleration of the healing of muscle tissue, nervous tissue or wounds; the acceleration or improvement of blood flow to damaged tissue; or the decrease of infection rate in damaged tissue, the method comprising administration to a patient In need thereof an effective amount of a long-acting growth hormone composition. 3. The method according to claim 1 or 2, wherein said composition comprises a growth hormone compound modified so as to provide a reduced clearance. 4. The method according to claim 1 or 2, wherein said composition comprises a growth hormone compound formulated in a sustained release formulation, 5. The method according to claim 1 or 2, wherein said composition comprises a growth hormone compound modified so as to provide a reduced clearance formulated in a sustained release formulation. 6. The use of a long-acting growth hormone composition in the manufacture of a medicament for the treatment of juvenile rheumatoid arthritis; cystic fibrosis, HIV-infection in children receiving HAART treatment (HIV/HALS children); hypochondrapiasia; achondroplasia; fractures in or of long bones, such as tibia, fibula, femur, humerus, radius, ulna, clavicula, mata-carpea, matatarsea, and digit; fractures in or of spongious bones, such as the scull, base of hand, and base of food; patients after tendon or ligament surgery In e.g. hand, knee, or shoulder; patients having or going through distraction oteogenesis; patients after hip or discus replacement, meniscus repair, spinal fusions or prosthesis fixation, such as in the knee, hip, shoulder, elbow, wrist or jaw; patients into which osteosynthesis material, such as nails, screws and plates, have been fixed; patients with non-union or mal-union of fractures; patients after osteatomia, e.g. from tibia or 1st toe: patients after graft Implantation; articular cartilage degeneration In knee caused by trauma or arthritis; osteoporosis in patients with Turner syndrome; osteoporosis in men; malnutritions! associated cardiovascular disease in APCD; reversal of cachexia in APCD; cancer in APCD; chronic abstractive pulmonal disease in APCD; HIV in APCD; elderly with APCD; chronic liver disease In APCD, fatigue syndrome in APCD; impaired liver function; males with HIV infections; short bowel syndrome; male infertility; patients after major elective surgery, a!coho|/drug detoxification or neurological trauma; osteo-arthritjs; or traumatically damaged cartilage. 7. The use of a long-acting growth hormone composition in the manufacture of a medicament for the healing of muscle tissue, nervous tissue or wounds; the acceleration ex' improvement of blood flow to damaged tissue; or the decrease of infection rate in damaged tissue. 8. The use according to daim 6 or 7, wherein said composition comprises a growth hormone compound which has been modified so as to provide a reduced clearance. 9. The use according to claim 6 or 7, wherein said composition comprises a growth hormone compound formulated in a sustained release formulation. 10. The use according to claim 6 or 7, wherein said composition comprises a growth hormone compound which has been modified so as to provide a reduced clearance formulated in a sustained release formulation,CLAIMS 1. A method for the treatment of juvenile rheumatoid arthritis; cystic fibrosis, HIV infection in children receiving HAART treatment (HIVfHALS children); hypochondroplasia; achondroplasia; fractures in or of long bones, such as tibia, fibula, femur, humerus, radius, ulna, clavi-cula, matacarpea, matatareea, and digit; fractures in or of spongious bones, such as the scull, base of hand, and base of food; patients after tendon or ligament surgery in e.g, hand, knee, or shoulder; patients having or going through distraction oteogenesis; patients after hip or discus replacement, meniscus repair, spinal fusions or prosthesis fixation, such as in the knee, hip, shoulder, elbow, wrist or jaw; patients into which osteosynthesis material, such as nails, screws and plates, have been fixed; patients with non-union or mal-union of fractures; patients after osteatomia, e.g, from tibia or 1st toe; patients after graft implantation; articular cartilage degeneration in knee caused by trauma or arthritis; osteoporosis in patients with Turner syndrome; osteoporosis in men; malnutrition! associated cardiovascular disease In APCD; reversal of cachexia in APCD; cancer In APCD; chronic abstractive pulmonary disease in APCD; HIV in APCD; elderly with APCD; chronic liver disease In APCD, fatigue syndrome In APCD; impaired liver function; males with Htv infections; short bowel syndrome; male infertility; patients after major elective surgery, aloohol / dmg detoxification or neurological trauma; osteoarthritis; or traumatically damaged cartilage, the method composing administering to a patient in need thereof an effective amount of a long-acting growth hormone composition. 2. A method for the acceleration of the healing of muscle tissue, nervous tissue or wounds; the acceleration or improvement of blood flow to damaged tissue; or the decrease of infection rate in damaged tissue, the method comprising administration to a patient In need thereof an effective amount of a long-acting growth hormone composition. The method according to claim 1 or 2, wherein said composition comprises a growth hormone compound modified so as to provide a reduced clearance. 4. The method according to claim 1 or 2, wherein said composition comprises a growth hormone compound formulated in a sustained release formulation, 5. The method according to claim 1 or 2, wherein said composition comprises a growth hormone compound modified so as to provide a reduced clearance formulated in a sustained release formulation. 6. The use of a long-acting growth hormone composition in the manufacture of a medicament for the treatment of juvenile rheumatoid arthritis; cystic fibrosis, HIV infection in children receiving HAART treatment (HIV / HALS children); hypochondrapiasia; achondroplasia; fractures in or of long bones, such as tibia, fibula, femur, humerus, radius, ulna, clavicula, mata-carpea, matatarsea, and digit; fractures in or of spongious bones, such as the scull, base of hand, and base of food; patients after tendon or ligament surgery In e.g. hand, knee, or shoulder; patients having or going through distraction oteogenesis; patients after hip or discus replacement, meniscus repair, spinal fusions or prosthesis fixation, such as in the knee, hip, shoulder, elbow, wrist or jaw; patients into which osteosynthesis material, such as nails, screws and plates, have been fixed; patients with non-union or mal-union of fractures; patients after osteatomia, e.g. from tibia or 1st toe: patients after graft Implantation; articular cartilage degeneration In knee caused by trauma or arthritis; osteoporosis in patients with Turner syndrome; osteoporosis in men; malnutrition! associated cardiovascular disease in APCD; reversal of cachexia in APCD; cancer in APCD; chronic abstractive pulmonary disease in APCD; HIV in APCD; elderly with APCD; chronic liver disease In APCD, fatigue syndrome in APCD; impaired liver function; males with HIV infections; short bowel syndrome; male infertility; patients after major elective surgery, a! coho | / drug detoxification or neurological trauma; osteoarthritis; or traumatically damaged cartilage. 7. The use of a long-acting growth hormone composition in the manufacture of a medicament for the healing of muscle tissue, nervous tissue or wounds; the acceleration ex 'improvement of blood flow to damaged tissue; or the decrease of infection rate in damaged tissue. 8. The use according to daim 6 or 7, wherein said composition comprises a growth hormone compound which has been modified so as to provide a reduced clearance. 9. The use according to claim 6 or 7, wherein said composition comprises a growth hormone compound formulated in a sustained release formulation. 10. The use according to claim 6 or 7, wherein said composition comprises a growth hormone compound which has been modified so as to provide a reduced clearance formulated in a sustained release formulation,